CD19 and congenital rubella syndrome: In a prospective study performed by Moreno-Castaño et al., the levels of several biomarkers between healthy controls and patients undergoing therapy with anti-CD19 or anti-B-cell maturation antigen (BCMA) CAR-T cells complicated by CRS and/or ICANS were compared [46].